As the number of users of obesity treatments increases, the competition for leadership over next-generation products is ...

Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on course for regulatory filings later this year. The readout from the TRIUMPH-1 ...

Eli Lilly on Thursday released results from TRIUMPH-1, its pivotal Phase 3 trial for the experimental obesity drug ...

The latest clinical trial results for retatrutide suggest this experimental drug could help adults with obesity shed more ...

Eli Lilly, a U.S. pharmaceutical company, announced that its next-generation obesity treatment under development achieved ...

New treatment option: FDA approved Zepbound in 2024 as the first drug specifically for obstructive sleep apnea in adults with obesity. Study-backed benefits: A JAMA study found GLP-1 users were less ...

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they ...

Ozempic and Mounjaro are both used to help manage blood sugar levels in people with type 2 diabetes. Ozempic is also approved to reduce the risk of heart attack and stroke, as well as reduce kidney ...

Seeking a trusted source of mounjaro in Dubai? You are the only one! This advanced treatment has become the best and most modern solution for weight maintenance and overall wellness. Dubai offers a ...

Retatrutide targets three hormones instead of one, helping trial participants achieve unprecedented levels of weight-loss ...